Secura   Report issue

For profit Phase 1 Phase 2
Founded: Las Vegas NV United States (2019)
Status: No NME R&D (2019)

Organization Overview

First Clinical Trial
2019
NCT03256045
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SECURA | SecuraBio | Secura Bio | Secura Bio, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 1)

Glioma (Phase 1)

Gliosarcoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 8